PRESS RELEASE published on 09/14/2023 at 14:30, 1 year 2 months ago Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 09/13/2023 at 14:30, 1 year 2 months ago Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
PRESS RELEASE published on 09/12/2023 at 14:30, 1 year 2 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
PRESS RELEASE published on 09/11/2023 at 14:30, 1 year 2 months ago Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
PRESS RELEASE published on 09/07/2023 at 14:30, 1 year 2 months ago Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
PRESS RELEASE published on 08/30/2023 at 14:30, 1 year 2 months ago The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
PRESS RELEASE published on 08/28/2023 at 14:30, 1 year 2 months ago Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
PRESS RELEASE published on 08/24/2023 at 13:00, 1 year 2 months ago Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
PRESS RELEASE published on 08/17/2023 at 14:30, 1 year 3 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 08/16/2023 at 14:30, 1 year 3 months ago Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Published on 11/22/2024 at 16:00, 1 hour 4 minutes ago Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Published on 11/22/2024 at 15:55, 1 hour 9 minutes ago Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 1 hour 49 minutes ago Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 2 hours 19 minutes ago Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs
Published on 11/22/2024 at 14:30, 2 hours 34 minutes ago Allied Universal Named Presenting Sponsor of 2024 Lott IMPACT Trophy Recognizing College Football's Defensive Best
Published on 11/22/2024 at 16:00, 1 hour 4 minutes ago AlphaX Makes Crypto Easier with Email Login and USDT Memecoins
Published on 11/22/2024 at 15:27, 1 hour 37 minutes ago EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
Published on 11/22/2024 at 14:46, 2 hours 17 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/22/2024 at 16:15, 49 minutes ago NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/21/2024 at 06:58, 1 day 10 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 1 day 10 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
